Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial
A new approach that prepares CAR-T cells before infusion achieved complete remission in 87% of patients with relapsed lymphoma, with most remaining cancer-free for two years.
Epigenetic priming of dual-target CAR-T cells with decitabine before infusion achieved exceptional and durable responses in relapsed/refractory B-cell lymphoma, with 87% complete responses and 77% 2-year PFS. Single-cell sequencing demonstrated that DAC priming enriches for memory-like progenitor T cells, potentially explaining superior durability compared to conventional CAR-T approaches.
What the study was
- Study design
- Open-label non-randomised Phase I/II trial (NCT04697940)
- Population
- Relapsed/refractory non-Hodgkin lymphoma patients
- Sample size
- 23
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Nature Communications
Why it surfaced
First clinical report of epigenetic (decitabine) priming strategy for dual-target CAR-T in NHL demonstrating 87% CRR and durable 2-year PFS 77% in a Phase I/II trial; mechanistically supported by single-cell sequencing; generalizable paradigm for engineered cell therapies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.